Facioscapulohumeral Muscular Dystrophy

Chapter

Abstract

Facioscapulohumeral muscular dystrophy is a common autosomal dominant muscular dystrophy with distinctive distribution of muscle weakness. This chapter discusses the etiology, pathogenesis, genetics, clinical manifestations, management, and prognosis of this disorder.

Keywords

FSHD Facioscapulohumeral muscular dystrophy chromosome 4q35 muscular dystrophy DUX4 scapular fixation Coat’s disease 

References

  1. 1.
    Flanigan KM, Coffeen CM, Sexton L, Stauffer D, Brunner S, Leppert MF. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul Disord. 2001;11(6–7):525–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Padberg GW. Facioscapulohumeral disease. Leiden: University of Leiden; 1982.Google Scholar
  3. 3.
    Wijmenga C, Sandkuijl LA, Moerer P, et al. Genetic linkage map of facioscapulohumeral muscular dystrophy and five polymorphic loci on chromosome 4q35-qter. Am J Hum Genet. 1992;51(2):411–5.PubMedGoogle Scholar
  4. 4.
    van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet. 1993;2(12):2037–42.PubMedCrossRefGoogle Scholar
  5. 5.
    Lemmers RJ, van der Vliet PJ, Klooster R, et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science. 2010;329(5999):1650–3.PubMedCrossRefGoogle Scholar
  6. 6.
    Gabriels J, Beckers MC, Ding H, et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene. 1999;236(1):25–32.PubMedCrossRefGoogle Scholar
  7. 7.
    van der Maarel SM, Tawil R, Tapscott SJ. Facioscapulohumeral muscular dystrophy and DUX4: Breaking the silence. Trends Mol Med. 2011;17(5):252–8.PubMedCrossRefGoogle Scholar
  8. 8.
    van der Maarel SM, Frants RR, Padberg GW. Facioscapulohumeral muscular dystrophy. Biochim Biophys Acta. 2007;1772(2):186–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Lemmers RJ, de Kievit P, Sandkuijl L, et al. Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere. Nat Genet. 2002;32(2):235–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kowaljow V, Marcowycz A, Ansseau E, et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul Disord. 2007;17(8):611–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Snider L, Asawachaicharn A, Tyler AE, et al. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: New candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet. 2009;18(13):2414–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Bosnakovski D, Xu Z, Gang EJ, et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 2008;27(20):2766–79.PubMedCrossRefGoogle Scholar
  13. 13.
    de Greef JC, Lemmers RJ, Camano P, et al. Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology. 2010;75(17):1548–54.PubMedCrossRefGoogle Scholar
  14. 14.
    de Greef JC, Lemmers RJ, van Engelen BG, et al. Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat. 2009;30(10):1449–59.PubMedCrossRefGoogle Scholar
  15. 15.
    Zeng W, de Greef JC, Chen YY, et al. Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet. 2009;5(7):e1000559.PubMedCrossRefGoogle Scholar
  16. 16.
    van Overveld PG, Lemmers RJ, Sandkuijl LA, et al. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. Nat Genet. 2003;35(4):315–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Snider L, Geng LN, Lemmers RJ, et al. Facioscapulohumeral dystrophy: Incomplete suppression of a retrotransposed gene. PLoS Genet. 2010;6(10):e1001181.PubMedCrossRefGoogle Scholar
  18. 18.
    FSH-DY Group. A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): Implications for therapeutic trials. The FSH-DY Group. Neurology. 1997;48(1):38–46.CrossRefGoogle Scholar
  19. 19.
    Awerbuch GI, Nigro MA, Wishnow R. Beevor’s sign and facioscapulohumeral dystrophy. Arch Neurol. 1990;47(11):1208–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Brouwer OF, Padberg GW, Ruys CJ, Brand R, de Laat JA, Grote JJ. Hearing loss in facioscapulohumeral muscular dystrophy. Neurology. 1991;41(12):1878–81.PubMedCrossRefGoogle Scholar
  21. 21.
    Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy. A general association with genetic and therapeutic implications. Brain. 1987;110(Pt 3):631–48.PubMedCrossRefGoogle Scholar
  22. 22.
    Desai UR, Sabates FN. Long-term follow-up of facioscapulohumeral muscular dystrophy and coats’ disease. Am J Ophthalmol. 1990;110(5):568–9.PubMedGoogle Scholar
  23. 23.
    Pauleikhoff D, Bornfeld N, Bird AC, Wessing A. Severe visual loss associated with retinal telangiectasis and facioscapulohumeral muscular dystrophy. Graefes Arch Clin Exp Ophthalmol. 1992;230(4):362–5.PubMedCrossRefGoogle Scholar
  24. 24.
    Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: Evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol. 1990;15(2):292–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Shields CL, Zahler J, Falk N, et al. Neovascular glaucoma from advanced coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol. 2007;125(6):840–2.PubMedCrossRefGoogle Scholar
  26. 26.
    Laforet P, de Toma C, Eymard B, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998;51(5):1454–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004;63(1):176–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Stubgen JP, Schultz C. Lung and respiratory muscle function in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2009;39(6):729–34.PubMedCrossRefGoogle Scholar
  29. 29.
    Funakoshi M, Goto K, Arahata K. Epilepsy and mental retardation in a subset of early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology. 1998;50(6):1791–4.PubMedCrossRefGoogle Scholar
  30. 30.
    Hobson-Webb LD, Caress JB. Facioscapulohumeral muscular dystrophy can be a cause of isolated childhood cognitive dysfunction. J Child Neurol. 2006;21(3):252–3.PubMedGoogle Scholar
  31. 31.
    Grosso S, Mostardini R, Di Bartolo RM, Balestri P, Verrotti A. Epilepsy, speech delay, and mental retardation in facioscapulohumeral muscular dystrophy. Eur J Paediatr Neurol. 2011;15(5):456–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Tawil R, van der Maarel S, Padberg GW, van Engelen BG. 171st ENMC international workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord. 2010;20(7):471–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Ricci E, Galluzzi G, Deidda G, et al. Progress in the molecular diagnosis of facioscapulohumeral muscular dystrophy and correlation between the number of KpnI repeats at the 4q35 locus and clinical phenotype. Ann Neurol. 1999;45(6):751–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Orrell RW, Tawil R, Forrester J, Kissel JT, Mendell JR, Figlewicz DA. Definitive molecular diagnosis of facioscapulohumeral dystrophy. Neurology. 1999;52(9):1822–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Lemmers RJ, O’Shea S, Padberg GW, Lunt PW, van der Maarel SM. Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Workshop 9th June 2010, LUMC, Leiden, The Netherlands. Neuromuscul Disord. 2011. doi:10.1016/j.nmd.2011.09.004.Google Scholar
  36. 36.
    Orrell RW, Copeland S, Rose MR. Scapular fixation in muscular dystrophy. Cochrane Database Syst Rev. 2010;(1):CD003278.Google Scholar
  37. 37.
    Ciafaloni E, Pressman EK, Loi AM, et al. Pregnancy and birth outcomes in women with facioscapulohumeral muscular dystrophy. Neurology. 2006;67(10):1887–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Rudnik-Schoneborn S, Glauner B, Rohrig D, Zerres K. Obstetric aspects in women with facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and congenital myopathies. Arch Neurol. 1997;54(7):888–94.PubMedCrossRefGoogle Scholar
  39. 39.
    van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology. 2004;63(4):702–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Olsen DB, Orngreen MC, Vissing J. Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology. 2005;64(6):1064–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Tawil R, McDermott MP, Pandya S, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology. 1997;48(1):46–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Kissel JT, McDermott MP, Mendell JR, et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology. 2001;57(8):1434–40.PubMedCrossRefGoogle Scholar
  43. 43.
    Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. Neurology. 2007;68(17):1428–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Payan CA, Hogrel JY, Hammouda EH, et al. Periodic salbutamol in facioscapulohumeral muscular dystrophy: A randomized controlled trial. Arch Phys Med Rehabil. 2009;90(7):1094–101.PubMedCrossRefGoogle Scholar
  45. 45.
    Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008;63(5):561–71.PubMedCrossRefGoogle Scholar
  46. 46.
    Zatz M, Marie SK, Passos-Bueno MR, et al. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet. 1995;56(1):99–105.PubMedGoogle Scholar
  47. 47.
    Griggs RC, Tawil R, McDermott M, Forrester J, Figlewicz D, Weiffenbach B, FSH-DY Group. Monozygotic twins with facioscapulohumeral dystrophy (FSHD): Implications for genotype/phenotype correlation. Muscle Nerve. 1995; Suppl 18:S50–S55.Google Scholar
  48. 48.
    Tawil R, Griggs RC. Facioscapulohumeral muscular dystrophy. In: Rosenberg RN, Prusiner S, DiMauro S, Barchi RL, editors. The molecular and genetic basis of neurological disease. 2nd ed. Oxford: Butterworth-Heinemann; 1997. p. 933. Chapter 52.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations